"Mercy Health - Springfield Heart House in Springfield, Ohio is one of Mercy Health's many Heart and Vascular Care locations serving communities across Ohio and Kentucky."

During the past decade, Heart House Research Foundation conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 3 clinical trials were completed, i.e. on average, 37.5% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 3 clinical trials were completed. i.e. 75% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Heart House Research Foundation" #1 sponsor was "Amgen" with 2 trials, followed by "American Regent, Inc." with 1 trials sponsored, "Boehringer Ingelheim" with 1 trials sponsored, "Brigham and Women's Hospital" with 1 trials sponsored and "Milestone Pharmaceuticals Inc." with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Heart House Research Foundation" #1 collaborator was "Duke Clinical Research Institute" with 2 trials as a collaborator, "Boston VA Research Institute, Inc." with 1 trials as a collaborator, "Medpace, Inc." with 1 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 1 trials as a collaborator and "Patient-Centered Outcomes Research Institute" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Heart House Research Foundation" are "Heart Failure" (3 trials), "ASCVD" (1 trials), "Atherosclerotic Cardiovascular Disease" (1 trials), "Atrial Fibrillation" (1 trials) and "Coronary Artery Disease" (1 trials). Many other conditions were trialed in "Heart House Research Foundation" in a lesser frequency.

Most popular intervention types in "Heart House Research Foundation" are "Drug" (5 trials), "Device" (2 trials), "Behavioral" (1 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "ACE-I (lisinopril) or ARB (losartan)" (1 trials), "Aptar Pharma Nasal Spray Bidose System" (1 trials), "Aspirin" (1 trials) and "Etripamil NS 70 mg" (1 trials). Other intervention names were less common.

The vast majority of trials in "Heart House Research Foundation" are 8 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Heart House Research Foundation". undefined are not yet recruiting, 2 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Heart House Research Foundation, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Heart House Research Foundation, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 1 trials that are defined as “Not Applicable".